References
- Boulton AJ, Vinik AI, Arezzo JC, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005;28:956-962
- National Diabetes Statistics, 2007. From the U.S. Department of Health and Human Services, National Institutes Of Health, National Diabetes Information Clearinghouse. Website: Available at: http://diabetes.niddk.nih.gov/DM/PUBS/statistics/DM_Statistics.pdf [Last accessed 2 February 2010]
- Boulton AJ. Management of diabetic peripheral neuropathy. Clin Diabetes 2005;23:9-15
- Hartsfield CL, Korner EJ, Ellis JL, et al. Painful diabetic peripheral neuropathy in a managed care setting: patient identification, prevalence estimates, and pharmacy utilization patterns. Popul Health Manag 2008;11:317-328
- Dworkin RH, O’Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007;132:237-251
- King SA. Diabetic peripheral neuropathic pain: effective management. Consultant Live 2008;48:11. Available at: http://www.consultantlive.com/display/article/10162/1337377. [Last accessed 2 February 2010]
- Argoff CE, Backonja MM, Belgrade MJ, et al. Consensus guidelines: treatment planning and options. diabetic peripheral neuropathic pain. Mayo Clin Proc 2006;81:S12-25
- Argoff CE, Cole BE, Fishbain DA, et al. Diabetic peripheral neuropathic pain: clinical and quality-of-life issues. Mayo Clin Proc 2006;81:S3-11
- Attal N, Cruccu G, Haanpää M, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006;13:1153-1169
- Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol 2003;60:1524-1534
- Cymbalta (duloxetine) Full Prescribing Information. Eli Lilly and Company, Indianapolis, IN, January 2010
- Argoff CE, Backonja MM, Belgrade MJ, et al. Diabetic peripheral neuropathic pain: consensus guidelines for treatment. J Fam Pract 2006;Suppl:3-19
- Lyrica (pregabalin) Full Prescribing Information. Pfizer Inc, New York, NY, December 2009
- Quilici S, Chancellor J, Löthgren M, et al. Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurol 2009;9:6
- Berger A, Dukes EM, Oster G. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain 2004;5:143-149
- Gore M, Brandenburg NA, Dukes E, et al. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage 2005;30:374-385
- Stewart WF, Ricci JA, Chee E, et al. Lost productive time and costs due to diabetes and diabetic neuropathic pain in the US workforce. J Occup Environ Med 2007;49:672-679
- Gordois A, Scuffham P, Shearer A, et al. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care 2003;26:1790-1795
- Ritzwoller DP, Ellis JL, Korner EJ, et al. Comorbidities, healthcare service utilization and costs for patients identified with painful DPN in a managed-care setting. Curr Med Res Opin 2009;25:1319-1328
- Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55
- Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat 1985;39:33-38
- White LA, Birnbaum HG, Kaltenboeck A, et al. Employees with fibromyalgia: medical comorbidity, healthcare costs, and work loss. J Occup Environ Med 2008;50:13-24
- Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22